Home＞BUSINESS
Nissui Pharma to Invest in Keio Univ. Spinoff Specializing in Saliva-Based Tests(Dec.28.2017)
Japanese clinical diagnostics supplier Nissui Pharmaceutical said on December 26 that it will invest 100 million yen in SalivaTech, a saliva testing upstart originating from Keio University, through a third-party share allocation scheme ...
(LOG IN FOR FULL STORY)
-
- J-TEC Submits Trial Protocol for Autologous Cultured Cartilage in Knee Osteoarthritis Use Jul.20
- Toray, Bonac to Begin US PI Trial of Nucleic Acid for IPF Jul.20
- Subcutaneous Vedolizumab Hits Primary Endpoint in PIII: Takeda Jul.20
- Takeda, Ovid Launching 3 New Studies for Rare Epilepsy Drug Jul.20
- Steep Hikes in Prices of Chinese-Made APIs Could Hit Generic Makers Hard Jul.20
- J-TEC Submits Trial Protocol for Autologous Cultured Cartilage in Knee Osteoarthritis Use(Jul.20)
- Toray, Bonac to Begin US PI Trial of Nucleic Acid for IPF(Jul.20)
- Subcutaneous Vedolizumab Hits Primary Endpoint in PIII: Takeda(Jul.20)
- Takeda, Ovid Launching 3 New Studies for Rare Epilepsy Drug(Jul.20)
- Steep Hikes in Prices of Chinese-Made APIs Could Hit Generic Makers Hard(Jul.20)
